Skip to content
MarketScale
‹ Back to IndustriesSciences

As Spaces Evolves into a “Normal Market”, How Will This Impact the Competition?

On the Space to Grow podcast, Astroscale’s Chris Blackerby and Charity Weeden bring their compelling experience and expertise to map out the technology, international policy, and scalability that will define the next generation of space exploration. In this episode, Kevin O’Connell discussed his career in government that led to his present business of informing and defining space commerce as a consultant…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Chris Blackerby · Space CommerceSpace Commerce ConsultingSpace EconomySpace Finance Community
Share

Key takeaways

01

On the Space to Grow podcast, Astroscale’s Chris Blackerby and Charity Weeden bring their compelling experience and expertise to map out the technology, international policy, and scalability that will define the next generation of space exploration.

02

In this episode, Kevin O’Connell discussed his career in government that led to his present business of informing and defining space commerce as a consultant…

Get featured

Want to get featured in MarketScale Sciences?

Create a free MarketScale workspace and get your company's expertise featured across our Sciences coverage. No credit card, no demo required.

Request an invite

On the Space to Grow podcast, Astroscale’s Chris Blackerby and Charity Weeden bring their compelling experience and expertise to map out the technology, international policy, and scalability that will define the next generation of space exploration.

In this episode, Kevin O’Connell discussed his career in government that led to his present business of informing and defining space commerce as a consultant for companies throughout the globe. As founder and CEO of Space Economy Rising, LLC, O’Connell speaks to the past and future of space commerce. With decades of experience working within government institutions, including the White House as well as speaking before US Congress committees on a variety of issues, O’Connell is uniquely positioned to provide insight into an industry that is both elusive and relevant.

When asked about his transition to the private sector, O’Connell spoke to his decision as follows:

“We’ve had a lot of folks talk to us over the last few years to say hey Kevin you just have to slow this all down. You have to slow all of this work down, especially in lower earth orbit. And, our view was that we looked very hard for data driven approaches to regulation we were going to regulate. What would be the analytic basis upon which we would do it.

We worked with the FCC when they issued their orbital debris mitigation guidelines to say okay what pieces of this rule are supported by what kinds of evidence. And, in a lot of cases there was a lot of wishful thinking but there wasn’t a lot of data rigorously collected to support that. And I would say that regulation that is uninformed and just based on wishful thinking can really do tremendous damage to an industry. So, you have to think about it that way. I think you do.”

This intriguing podcast goes on to explore O’Connell’s transition out of government and to what he is doing now in the private sector as well as what lessons he is bringing forward into his present business.

Of the many hats O’Connell wears, the most significant of his present contributions is in the field of space economy. This includes advising companies on

  • Space Industry
  • Technology
  • Space finance community
  • Basics that must be done as an early-stage company in this field
  • Competitors
  • Orbital debris mitigation strategies
  • Cyber security strategies
  • Investment Risk Management
  • And much more.

Tune in to learn from this renowned expert as the discussion covers everything from how he got to where he is to what he envisions for the future of space economy.

More in This Series

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Get your team featuredSee how it works15 minutes, straight to a calendar.

About the author

CB
Chris Blackerby

Follow Sciences Insights

Get new expert content in your inbox.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Telehealth "digital waiting rooms" are turning into premium pharma ad slots

Telehealth "digital waiting rooms" are turning into premium pharma ad slots

Pharmaceutical companies are increasingly using telehealth digital waiting rooms as prime advertising slots. These virtual spaces offer unique opportunities for pharma brands to engage patients before and after their virtual care visits. The trend is driven by fresh data on patient attention and strategic execution by agencies.

  • 01Pharmaceutical brands are using digital waiting rooms in telehealth platforms as premium ad slots.
  • 02New patient-attention data enhances pharma media plans for virtual care settings.
  • 03Virtual waiting rooms allow targeted patient engagement before and after healthcare consultations.

Aug 29, 2026

Roche pTau217 clearance and Labcorp’s Alzheimer’s test bring diagnostics to primary care

Roche pTau217 clearance and Labcorp’s Alzheimer’s test bring diagnostics to primary care

Recent advancements in Alzheimer’s pathology tests and lab automation are transforming diagnostics by moving the bottleneck from assay availability to workflow activation. These developments are making it feasible for primary care facilities to access cutting-edge diagnostic tools. This shift promises to enhance early detection and treatment strategies for Alzheimer's disease.

  • 01Lab automation is helping to remove bottlenecks in workflow activation for Alzheimer’s diagnostics.
  • 02Primary care facilities are gaining access to advanced Alzheimer’s diagnostic tests.
  • 03Early detection and treatment of Alzheimer's disease could be improved by these new diagnostic tools.

Aug 28, 2026

Genentech’s $750M Hillsboro build adds device fill-finish capacity by 2031

Genentech’s $750M Hillsboro build adds device fill-finish capacity by 2031

Genentech is investing $750 million in a new fill-finish plant in Hillsboro. The facility will focus on the production of prefilled syringes and autoinjectors. The site is expected to become operational in 2031.

  • 01Genentech is investing $750 million in a new Hillsboro facility.
  • 02The facility will produce prefilled syringes and autoinjectors.
  • 03Operations at the plant are expected to begin in 2031.

Aug 27, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

CB
Chris Blackerby

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512